Equities researchers at Zacks Small Cap lowered their Q2 2025 earnings per share (EPS) estimates for shares of Arrowhead Pharmaceuticals in a report issued on Wednesday, February 12th. Zacks Small Cap ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback